Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

This EIJ image highlights a new device designed to enhance the safety and efficiency of ViV TAVI procedures, particularly TAV-in-TAV, by reducing attempts to cross the valve and preventing guidewire misnavigation, thereby minimizing complications and procedure time.

Ali Nazmi Calik provides his take on UNIVERSAL randomized clinical trial, which questioned whether routine ultrasonography guidance for CFA access for cardiac procedures reduces bleeding or vascular complications. This trial was presented by Sanjit S. Jolly during TCT 2022.